Registry for Chronic Obstructive Pulmonary Disease With Anxiety and Depression in China

Depression Clinical Trial

Official title:

The Early Detection, Clinical Course and Prognosis of Anxiety and Depression in Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03187236
• Other study ID #: 2016YFC1304404A
• Status: Recruiting
• Phase: N/A
• First received: June 13, 2017
• Last updated: June 13, 2017
• Start date: June 15, 2017
• Est. completion date: December 31, 2020

Study information

• Verified date: June 2017
• Source: Chinese Academy of Medical Sciences, Fuwai Hospital
• Contact: Jiangna Han, MD
• Phone: 13520053104
• Email: 13520053104[@]139.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Anxiety and depression are common comorbidities of chronic obstructive pulmonary disease (COPD). However, the exact prevalence is not known in China. COPD patients with anxiety and depression tend to have more severe symptoms and worse prognosis, but the related evidences are not strong enough. The study aim to investigate the prevalence and long-term outcome of anxiety and depression in COPD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1906
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Gender: All
• Age group: N/A to 80 Years

Eligibility

Inclusion Criteria:

• Stable chronic obstructive pulmonary disease (COPD) patients

Exclusion Criteria:

• Patients with bronchial asthma or other severe pulmonary diseases or having received pulmonary surgery in 6 months

• Patients with tumor history during past 5 years

• Patients with COPD exacerbations during past 4 weeks

• Participants in clinical trials

• Patients in pregnancy or breastfeeding

• Patients unable to complete questionaire independently

• Patients older than 80 years old

• Patients receiving long-term domiciliary oxygen therapy

Related Conditions & MeSH terms

• Anxiety
• Anxiety Disorders
• COPD
• Depression
• Depressive Disorder
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	moderate and severe COPD exacerbations	total times	3 years
Secondary	All-cause mortality	mortality in %	3 years